Four Distinct Subtypes of Alzheimer’s Disease Based on Resting-State Connectivity Biomarkers

Pindong Chen,Hongxiang Yao,Betty M. Tijms,Pan Wang,Dawei Wang,Chengyuan Song,Hongwei Yang,Zengqiang Zhang,Kun Zhao,Yida Qu,Xiaopeng Kang,Kai Du,Lingzhong Fan,Tong Han,Chunshui Yu,Xi Zhang,Tianzi Jiang,Yuying Zhou,Jie Lu,Ying Han,Bing Liu,Bo Zhou,Yong Liu
DOI: https://doi.org/10.1016/j.biopsych.2022.06.019
IF: 12.81
2022-01-01
Biological Psychiatry
Abstract:BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder with significant heterogeneity. Different AD phenotypes may be associated with specific brain network changes. Uncovering disease heterogeneity by using functional networks could provide insights into precise diagnoses. METHODS: We investigated the subtypes of AD using nonnegative matrix factorization clustering on the previously identified 216 resting-state functional connectivities that differed between AD and normal control subjects. We conducted the analysis using a discovery dataset (n = 809) and a validated dataset (n = 291). Next, we grouped individuals with mild cognitive impairment according to the model obtained in the AD groups. Finally, the clinical measures and brain structural characteristics were compared among the subtypes to assess their relationship with differences in the functional network. RESULTS: Individuals with AD were clustered into 4 subtypes reproducibly, which included those with 1) diffuse and mild functional connectivity disruption (subtype 1), 2) predominantly decreased connectivity in the default mode network accompanied by an increase in the prefrontal circuit (subtype 2), 3) predominantly decreased connectivity in the anterior cingulate cortex accompanied by an increase in prefrontal cortex connectivity (subtype 3), and 4) pre-dominantly decreased connectivity in the basal ganglia accompanied by an increase in prefrontal cortex connectivity (subtype 4). In addition to these differences in functional connectivity, differences between the AD subtypes were found in cognition, structural measures, and cognitive decline patterns. CONCLUSIONS: These comprehensive results offer new insights that may advance precision medicine for AD and facilitate strategies for future clinical trials.
What problem does this paper attempt to address?